University of Northern Colorado

Scholarship & Creative Works @ Digital UNC
Master's Theses

Student Research

12-9-2022

Immunological Effects of Berberine and Physical Activity in a
Murine Breast Cancer Model
Janae Mudge
janae.mudge@unco.edu

Follow this and additional works at: https://digscholarship.unco.edu/theses

Recommended Citation
Mudge, Janae, "Immunological Effects of Berberine and Physical Activity in a Murine Breast Cancer
Model" (2022). Master's Theses. 265.
https://digscholarship.unco.edu/theses/265

This Dissertation/Thesis is brought to you for free and open access by the Student Research at Scholarship &
Creative Works @ Digital UNC. It has been accepted for inclusion in Master's Theses by an authorized administrator
of Scholarship & Creative Works @ Digital UNC. For more information, please contact Jane.Monson@unco.edu.

© 2022
Janae R. Mudge
ALL RIGHTS RESERVED

UNIVERSITY OF NORTHERN COLORADO
Greeley, Colorado
The Graduate School

IMMUNOLOGICAL EFFECTS OF BERBERINE
AND PHYSICAL ACTIVITY IN A MURINE
BREAST CANCER MODEL

A Thesis Submitted in Partial Fulfillment of the
Requirements for the Degree of
Master of Science

Janae R. Mudge

College of Natural and Health Sciences
School of Biological Sciences
Biological Sciences

December 2022

This Thesis by: Janae R. Mudge

Entitled: Immunological effects of berberine and physical activity in a murine breast cancer
model
has been approved as meeting the requirements for the Degree of Master of Science in College of
Natural Health Sciences in the School of Biological sciences

Accepted by the Thesis Committee:

Dr. James Haughian Ph.D., Research Advisor

Dr. Nicholas Pullen Ph.D., Committee Member

Dr. Nicole Withrow Ph.D., Committee Member

Accepted by the Graduate School

Jeri-Anne Lyons, Ph.D.
Dean of the Graduate School
Associate Vice President for Research

ABSTRACT
Mudge, Janae R. Immunological effects of berberine and physical activity in a murine breast
cancer model. Unpublished Master of Science Thesis, University of Northern Colorado,
2022.

Berberine (BBR) is a plant-derived alkaloid popularly used in a complementary context
to treat splenomegaly and chronic disease states such as rheumatoid arthritis, diabetes, and
cancer. Recent research has examined BBR as a regulator of lipid and glucose metabolism in
association with the AMPK pathway; but little is known concerning its immunological impacts.
It is also known that exercise is a potent AMPK activator exhibiting immunological benefits, but
nothing is known about the combination of these complementary approaches for treating breast
cancer. The purpose of this study is to determine if oral consumption of BBR when paired with
physical activity will increase T lymphocyte activation while decreasing the presence of
myeloid-derived suppressor cells (MDSC) within the tumor microenvironment, spleen, bone
marrow, and blood of the immunocompetent BALB/c 4T1 mammary adenocarcinoma model.
We hypothesize that subjects treated with this combination will have reduced MDSC counts, and
increased T cell infiltration and activation in tissues of interest, effector, and regulatory subsets.
Our data indicates no intervention specific change in NUR77 presence—a transcription factor
expressed in antigen specific activation of T cells—in the spleen, lungs and tumor
microenvironment of tumor bearing mice. However, T regulatory lymphocyte FOXP3 was also
assessed and found to increase significantly in the lungs of tumor-bearing mice. These findings
suggest BBR paired with physical activity may have significant immunological implications on
iii

T cell activation broadly, and infiltration into the tumor microenvironment. These findings
directly inform those who practice complementary and alternative supplementation, an area
lacking immunological analysis, including raising concerns for the impact on aberrant,
potentially undesirable Treg function.

iv

ACKNOWLEDGEMENTS
My time at The University of Northern Colorado (UNCO) has left me with wonderful
memories, many valuable skills and connections with great mentors and friends. Dr. James
Haughian and Dr. Nick Pullen were wonderful advisors and taught me a great deal. I am very
thankful for their investment in my path as a scientist and a student. Thank you to you both for
your guidance and support. Through working with and observing each of you I learned what it
means to be a scientist, and an educator. James, I enjoyed teaching advanced physiology under
you and look back fondly on the crazy times that we navigated throughout those initial pandemic
teaching years. Nick, I appreciate the hours of time you invested in me every week whether it
was meeting to go over protocols, teaching me flow cytometry, helping me in the lab, or
allowing me to utilize resources in your lab. You treated me just like one of your graduate
students and allowed me to fully identify myself as one of your graduate students, and I am very
grateful.
I am also appreciative to my committee member and mentor Dr. Nikki Withrow. Thank
you Dr. Withrow for your constant encouragement and investment in my future even beyond
graduate school. Over the last two years when I needed encouragement you were always there to
speak through my uncertainty.
I am also thankful for my lab mates, Travis Russo, David Lyons, Lea Haverbeck and Arj
Ramani. Travis, you hung in there with me from the very first 18-hour lab day until the very last.
We shared so many memories and I will forever be grateful. You’re great at extracting bone
marrow, and willingly checked my dilution math (or just did it for me) when I was deliriously
v

tired. Thank you for being the person I could always count on to do things right. I would also
like to thank my undergraduate, Grace, for being a tremendous help in the lab, with feeding mice
berberine gummies, and always showing up with a willingness to learn.
I would also like to extend thanks to my fellow TA’s within the School of Biological
Science. Eric Januszkiewicz thank you for being the best classmate and friend anyone could ask
for. You taught me so much, worked alongside me, and brought me food more times than I can
count. Jessie Pollart and Kelsey Krutsinger, we made it through some tough semesters, but I
would not have wanted to do it alongside anyone else.
Lastly, I would like to express my gratitude to my family. My parents and sisters who put
up with me over the course of my graduate degree, ensured I was eating, provided me a place to
stay, and helped me with everything from editing my thesis, to talking through protocols, to
fixing my car the many times it broke down. My parents provided me with more love and
grounding than I deserved over the past two years, and my sisters made sure I didn’t spend every
waking moment in the lab. I am also grateful to Karen and Frank for their unwavering support
and all the time Frank invested in helping me investigate berberine.
To everyone who played a role in my graduate education I am thankful—your sacrifice
and investment in my educational journey has not gone unnoticed.

vi

TABLE OF CONTENTS
CHAPTER
I.

II.

III.

INTRODUCTION………………………………………………………………….

1

Historical Progression of Cancer Treatment……………………………………….
Herbal Interventions………………………………………………………..
Immune Modulating Influence of Exercise and Physical Activity.………..
Study Purpose and Hypothesis…………………………………………….
Research Hypothesis……………………………………………………………….

1
1
2
2
3

REVIEW OF THE LITERATURE………………………………………………...

4

Immunologically and Metabolically Relevant Modulatory
Impact of Berberine and Physical Activity ………………………………………..
Immune Mediated Neoplastic Modulation………………………………...
Berberine: The ‘Poor Man’s’ Metformin…………………………………..
Metabolic Influence of Berberine………………………………………….
Adenosine Monophosphate-Activated Protein Kinase and Energy
Metabolism in Cancer……………………………………………………...
Physical Activity and Cancer in the Immune System……………………...
Breast Cancer in the Context of Berberine and Physical Activity…………
Berberine and Immune Activity…………………………………………....
Immune Cell Activation…………………………………………………....
Study Rationale………………………………………………………………….....

9
10
11
13
13
14

METHODOLOGY…………………………………………………………………

16

Materials and Protocol Models…………………………………………………….
Animal Care………………………………………………………………..
Berberine Supplementation ………………………………………………..
Exercise Wheel Run Model………………………………………………...
Fluorescent 4T1 Tumor Inoculation and Measurement…………………………....
Cell Growth and Stable Plasmid Insertion…………………………………
Tissue Preparation and Analysis…………………………………………………...
Cellular Permeabilization, Flow Cytometry and Antibody Staining………………
Gating for Flow Cytometry………………………………………………...
Statistical Analysis………………………………………………………...

16

vii

4
4
5
7

16
16
19
20
20
24
25
26
30

RESULTS…………………………………………………………………………..

31

Impacts of Berberine Supplementation on Cancer Progression and Physical
Activity……………………………………………………………………………..
Physical Activity and Wheel Running Volume……………………………
Metastasis to the lungs……………………………………………………..
Tumor and Spleen Mass…………………………………………………....
Immune Markers…………………………………………………………………...
CD11B Leukocytic Immune Populations………………………………….
Myeloid-Derived Suppressor Cell Immune Subsets……………………….
CD3+ and CD4+ T Effector Subsets………………………………………
Resident and Circulating Cytotoxic T Lymphocytes………………………
Tissue Specific Infiltration of CD4+CD24+ FoxP3+ T-regulatory Cell…….
Activation Status (Nur77) …………………………………………………

31
32
34
36
38
38
40
43
46
48
51

DISCUSSION AND CONCLUSIONS…………………………………………….

54

Discussion………………………………………………………………………….
Berberine May Impact Physical Activity and Wheel Running Volume…...
Metastasis to the Lungs……………………………………………………
Spleen and Tumor Mass …………………………………………………..
Myeloid-Derived Immune Populations…………………………………….
Lymphoid Derived Immune Populations………………………………….
T Regulatory Cells in the Context of Berberine, Physical Activity and
Cancer ……………………………………………………………………...
Bioavailability of Orally Administered Berberine…………………………
Conclusion………………………………………………………………………….

54
55
56
57
58
59

REFERENCES…………………………………………………………............................

66

APPENDIX
A
Institutional Animal Care and Use Committee Approval………………………….

77

Supplemental Figures……………………………………………………………...

79

IV.

V.

B

viii

61
63
64

LIST OF FIGURES
FIGURE
1.
Study Design and Interventions………………………………………. 18
2.

tdT Expressing 4T1 Cells……………………………………………..

3.

Red Fluorescent Protein Addition to the Genome of 4T1 Mammary
Carcinoma Cells………………………………………......................... 23

4.

Extracellular and Intracellular Gating Strategy Represented by Spleen
Tissue…………………………………………………………………. 27

5.

Lung Fluorescence Gating Strategy…………………………………... 28

6.

MDSC Gating Strategy……………………………………………...... 29

7.

Wheel Running Volume in BALB/c 4T1 Tumor Bearing Female
Mice………………………………………………………………....... 33
.
Fluorescence Intensity Within the Lungs of Tumor Bearing BALB/c
Mice at 4 Weeks Post Injection with 4T1 Mammary Carcinoma…….. 35

8.

21

9

Comparative Spleen and Tumor Mass Between Treatment Groups….. 37

10.

Accumulation of Total CD11B Count Across All Tissue Samples…... 39

11.

LY6C MDSC Cell Counts Represented Across All Tissues………….

12.

LY6G MDSC Cell Counts Represented Across All Tissues…………. 42

13.

Frequency of Lymphocytes Within the Spleen of Tumor and NonTumor Bearing BALB/c Mice………………………………………...

44

14.

Frequency of Lymphocytes Within Tumors of BALB/c Mice………..

45

15.

Frequency of Lymphocytes Within the Blood of Tumor and NonTumor Bearing BALB/c Mice………………………………………...

47

Frequency of Lymphocytes Within the Lung of Tumor and NonTumor Bearing BALB/c Mice…………………………………….......

49

FOXP3 Specific Variation Within Various Tissues…………………..

50

16.

17.

ix

41

18.

Nurr77 Expression Within the Spleen and Tumor of Each Control
and Intervention Group……………………………………………….. 52

19.

Nurr77 expression within the blood and lung of each control and
intervention group…………………………………………………….. 53

x

LIST OF TABLES
TABLE
1

2

Outline of Intervention and Control Groups, Descriptive Abbreviations,
and Sample Size………………………………………………………….

19

Biomarker Profiles, Antibody Catalog Numbers and Suppliers…………

25

xi

1

CHAPTER I
INTRODUCTION
Historical Progression of Cancer Treatment
Recent statistical measures suggest that progress has been made in the fight against cancer.
However, much of the observed reduction in metastatic cancer-related death is associated with
preventative efforts. For example, improved testing sensitivity leading to increased rates of early
detection, and community health measures such as reduced smoking rates (Liu et al., 2015;
Simon, 2020). While these efforts have led to some reduction in cancer related deaths, neoplastic
disease evading these efforts are recalcitrant to decades-old standard of care (chemo- and
radiotherapy with surgery). In response to this realization, clinical treatments are shifting from
these older practices alone to integrative and immunotherapy-based interventions. This new
focus on complimentary and nutraceutical interventions is leading to a subsequent shift in
research efforts. Integrative (sometimes referred to as complimentary) interventions include
administration of isolated nutrients, potential cancer vaccines, whole diet interventions, and
prescription exercise. However, the highly mutagenic and metastatic nature of many cancers
makes studying the mechanistic impact of integrative interventions difficult (Hanahan &
Weinberg, 2011).
Herbal Interventions
Herbal interventions are the foundation of historical medical practice and continue to exert a
marked influence on modern treatments. Berberine (BBR) is a plant-derived alkaloid that is
popularly used in a complementary context to treat splenomegaly and chronic disease states such
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as rheumatoid arthritis, hyperinsulinemia, diabetes, and cancer (Malhotra et al., 2021; Vita et al.,
2021). Recent research has examined BBR as a regulator of lipid and glucose metabolism in
association with the AMPK pathway, but little is known concerning its immunological impacts.
However, recent evidence shows immunosuppressive functions on specific effector T
lymphocyte subsets such as CD4+ T helper cells (Th) (Vita et al., 2021). T regulatory (Treg)
subsets of Th cells are of great interest in the cancer immunology field as Tregs pose a problem
due to their negative impact in the tumor microenvironment and subsequent vital function in
peripheral tissues for maintaining immunological homeostasis (Weinhold et al., 2016).
Consistent long-term exercise is thought to increase Treg frequency in a healthy population and is
supposed to possibly suppress Treg tumor recruitment (Hagar et al., 2019).
Immune Modulating Influence of
Exercise and Physical Activity
It is also known that exercise is a potent AMPK activator exhibiting immunological benefits,
but nothing is known about combination of these two complementary approaches for treating
breast cancer. Exercise is also a rising topic of research within the field of cancer immunology.
Epidemiological data suggest that physical inactivity is increasing on a global level which
contributes to concerning levels of neoplastic evading disease, obesity epidemics, and increased
risk of autoimmunity. As a solution to widespread disease risk, consistent moderate intensity
physical activity has been found to modulate immune activity effectively decreasing a patient's
risk for multiple disease states including breast cancer (McTiernan et al., 2003).
Study Purpose and Hypothesis
The purpose of this study is to determine if oral consumption of BBR when paired with
physical activity will increase T lymphocyte presence and activation status while decreasing the
presence of myeloid-derived suppressor cells (MDSC) within the tumor microenvironment,
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spleen, bone marrow, and blood of both a healthy population of immunocompetent BALB/c
mice and a BALB/c 4T1 mammary carcinoma model. The impact of BBR on voluntary exercise
volume will be examined and lastly, the impact of voluntary oral BBR supplementation with or
without physical activity on metastasis to the lungs of mice inflicted with 4T1 mammary
carcinoma will be assessed. The findings of this study will directly inform those who practice
complementary and functional medicine, an area lacking immunological analysis, including
raising concerns for the impact on aberrant, potentially undesirable Treg function.
Research Hypotheses

H1

Mice treated with BBR while concurrently engaging in an extended period
of physical activity will exhibit reduced MDSC counts in addition to
increased T cell counts and activation response in the lungs, tumor
microenvironment, spleen, and blood.

H2

Voluntary wheel running will decrease in the presence of oral BBR
supplementation.

H3

A combination of physical activity and BBR treatments will additively
decrease 4T1 metastasis to the lungs.
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CHAPTER II
REVIEW OF THE LITERATURE
Immunologically and Metabolically Relevant Modulatory
Impact of Berberine and Physical Activity
Immune Mediated Neoplastic
Modulation
T Lymphocytes
Tumor infiltrating lymphocytes have been extensively studied in the context of cancer,
however minimal research has paired BBR with physical activity in a neoplastic context. Within
the tumor microenvironment the presence of cells among the lymphocyte lineage of the adaptive
immune system performs various immune-tumor mediated interactions including immune
suppression and cytotoxicity. A large proportion of these immune-neoplasm interactions revolve
around a component of the immune system known as T lymphocytes. T lymphocytes, also
known as T cells, are distinguished from other lymphocytes by the CD3+ T cell receptor complex
(TCRC) present on mature T cells. T cells can be further identified by co-receptor markers on
their surface. CD4 is a marker present on T helper (Th) lymphocytes that plays a role in the
activation of antibody producing B Lymphocytes as well as gives rise to a subset of fork-head
box protein P3 (Fox-P3) transcription factor expressing Tregs. CD4+CD24+ Tregs, and a myeloid
lineage of cells known as MDSC’s, along with tumor-associated macrophages, are generally
accepted as the prominent immunosuppressive agents within the immune system (Chuckran et
al., 2021). As such, Tregs play an important role in a healthy immune response by maintaining
homeostatic control through suppressing overactivity of the immune system. This function can
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be exploited in the tumor microenvironment where T regs are actively promoted and their
immunoprotective function is hijacked to inhibit anti-tumor immunity (Chuckran et al., 2021).
Cytotoxic CD8+ T-lymphocytes have the opposite function and are well characterized as immune
cells with anti-tumor properties. CD8+ T-lymphocytes play an important role in protecting the
host from neoplastic disease and viral infection. These cells are thought to increase significantly
in circulation after moderate exercise (Garritson et al., 2020). However, this increase is short
lived following physical activity which supports the idea that consistent exercise is key to
enhanced immunity and therefore greater protection against cancerous disease.
Myeloid-Derived Suppressor Cells
Cancer is infamous for its ability to circumvent natural immune defenses by emulating
“self” and thereby effectively hiding from the immune system. This guise is accomplished, in
part, through the recruitment of a lymphoid population known as CD11B+ myeloid-derived
suppressor cells (MDSC’s). MDSC’s are a host of immature immune cells stemming from
myeloid origin. MDSC’s works in concert with each other to suppress the activity of the immune
system in specific contexts such as cancer or pregnancy (Ostrand-Rosenberg & Fenselau, 2018).
Phenotyping paired with identification of suppression in immune cell populations, such as CD4 +
T-helper cells, is one of the most effective ways to identify this mixture of cells (OstrandRosenberg & Fenselau, 2018). Indeed, MDSC’s immunosuppressive nature plays a significant
role in metastatic dissemination of cancer cells while also creating an environment that is
favorable for tumor growth (Ugel et al., 2015).
Berberine: The ‘Poor Man’s’ Metformin?
In the past 5 years nutraceuticals have risen in popularity and are quickly becoming a
pharmacological phenomenon. Nutraceutical is a term referring to naturally occurring
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compounds that claim to alter physiology in a similar manner to a specific pharmaceutical and
therefore can be used alongside or as a replacement for a traditional medication. Berberine
(BBR), a common herbal supplement, has been prescribed through the ages in Eastern cultures as
a non-pharmaceutical prescription. Much of this age-old use of BBR relates to its pleiotropic
properties that have led to widespread use within the lay public, complementary medicine
community and even some traditional medicine practices specifically for treatment of conditions
with significant metabolic impact, such as diabetes and PCOS (Malhotra et al., 2021). As a
supplement, the lay public utilizes BBR to increase athletic performance, enhance immunity,
manage glucose metabolism, increase insulin sensitivity in PCOS and type 2 diabetes, and as
treatment for bacterial diarrhea. Moreover, the general American population may be consuming
BBR unknowingly as the compound also termed as Natural Yellow-18 and utilized as a color
additive in the food industry (Pereira et al., 2008). Within the scientific community BBR may
also have utility in staining for secretory activity of mast cells (Berlin & Enerbäck, 1983) It is
well characterized that the antimicrobial properties of BBR impacts the gut microbiome which in
turn may account for some of the metabolic and immunological influence BBR exhibits within
the body (L. Zhang et al., 2021).
Structurally, BBR is a hydrophobic isoqualine alkaloid and possesses molecular
characteristics resembling cholesterol (el Khalki et al., 2020). It has been widely studied in the
context of diabetes as well as lipid metabolism, and more recently has appeared in cancer and
autoimmunity research. BBR exhibits similar physiological mechanisms to the common
pharmacological insulin sensitizer commonly known as Metformin, which functions as a mild
inhibitor of cytochrome complex 1 in the mitochondrial electron transport chain (Andrzejewski
et al., 2014; Bridges et al., 2014; Griss et al., 2015). While the molecular mechanisms will be
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described below, BBR is well characterized as an insulin sensitizer through its ability to
upregulate insulin receptor expression in muscle and hepatic tissue which allows for increased
response to circulating insulin and greater glucose absorption (H. Zhang et al., 2010). Due to its
metformin-like glucose regulating properties along with its inexpensive cost and easy nonprescription access, berberine has been coined the “poor man’s metformin”. Furthermore,
clinical European guidelines have already approved BBR as a long-term non-prescription
nutraceutical for dyslipidemia patients with low tolerance for statins (Rondanelli et al., 2020).
BBR has also been found to desensitize doxorubicin (DOX) resistant cancer cells. When
administered alongside this common chemotherapeutic there was a dose-dependent incidence of
apoptosis among breast cancer cells that were thought to be DOX resistant (Pan et al., 2017).
Metabolic Influence of Berberine
Both BBR and Metformin alter the function of a metabolic pathway known as AMPactivated protein kinase (AMPK) and exert a similar physiological influence through
upregulation of this pathway which primarily alters energy metabolism (Xu et al., 2020; Zhao et
al., 2021). Increases in AMPK activity artificially mimic metabolic processes that naturally occur
during fasting and result in a marked influence on fatty acid oxidation, as well as hepatic and
muscular sensitization to glucose and insulin (Gillespie et al., 2016). These pathways are
hijacked in the tumor microenvironment and utilized for the benefit of a growing tumor, making
pathways such as AMPK popular targets for anti-cancer interventions. AMPK also influences
metabolism within T-cells in response to nutrient availability (E. H. Ma et al., 2017). Metformin
has been found to increase the efficacy of CD8+ T-cells and the development of memory T cells
when administered alongside an experimental anti-cancer vaccine (Pearce et al., 2009).
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Metformin’s insulin sensitizing action can also decrease risk of tumorigenesis through decreased
insulin levels, and down regulation of nuclear factor-κ B (NF-κ B) (Podhorecka et al., 2017).
Although Metformin is currently considered a first line treatment for type 2 Diabetes
Mellitus, recent studies are elucidating the drug’s potential as an anti-aging intervention as well
as possible use in specific cancers, such as mammary carcinoma (Campbell et al., 2017).
Research has suggested that Metformin’s may possess life extending properties that stem from
its ability to mimic calorie restriction without fasting or introduction of malnutrition (Campbell
et al., 2017; Gillespie et al., 2016). The mechanisms activated by calorie restriction—including
inhibition of MTOR, decreased insulin signaling, and activation of AMPK—are extensively
studied and have been found to promote longevity through cellular disease evading strategies
such as autophagy leading to apoptosis of cancer cells (Knapowski et al., 2002). Furthermore,
calory restrictive mechanisms have an inherently negative impact on diseases, such as cancer,
that depend on accessibility of biomolecules and energy generation to fuel rapid proliferation. In
line with this theory, patients taking metformin as a diabetes treatment have been found to
exhibit reduced development of breast cancer which further validates its theorized
oncoprotective properties (Gillespie et al., 2016). Increased cancer rates are paired with poor
nutritional quality and excessive calorie intake within developed countries makes the study of
calorie restricting mimetics and their possible life extending benefits within a healthy population
of great scientific interest. This supports the need for research efforts exploring if BBR
supplementation may possess similar promise for both diseased and healthy patients as a nonprescription intervention with metformin like effects (Podhorecka et al., 2017).
Breast cancer is currently the most prevalent cancer type in both developed and
developing countries alike (el Khalki et al., 2020). As of 2018 approximately 18% of breast
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cancer cases were an aggressive triple negative form of cancer with very limited treatment
options (el Khalki et al., 2020). The primary non-hormonal treatment for this type of breast
cancer is known as cytotoxic chemotherapy (el Khalki et al., 2020). One classes of cytotoxic
chemotherapy is anthracycline drugs such as doxorubicin (Lipodox) and valrubicin (Valstar).
This therapy type is systemically devastating and varies in efficacy. In an effort to uncover
treatment options with fewer negative side effects and also to reduce the need for polypharmacy,
researchers are delving into the possibilities of BBR as a complementary treatment option.
Although metformin and exercise both exert influence on AMPK, there is thought that when
these two interventions are combined metformin may decrease exercise volume (Ramos et al.,
2020). It is currently unknown if BBR exhibits the same reduction in exercise volume.
Adenosine Monophosphate-Activated
Protein Kinase and Energy
Metabolism in Cancer
As stated above, BBR is thought to be a stimulator of AMP-Activated Protein Kinase
(AMPK). AMPK functions as a metabolic cellular ATP/ADP sensor recognizing and playing a
role in maintaining energy levels within the cell (Pan et al., 2017). The findings of Faubert et al.,
suggest that AMPK activity inhibits tumor development through its role in the metabolic cycle of
the cell which effectively reverses Warburg metabolism (Faubert et al., 2013). The Warburg
effect is a metabolic shift unique to cancer cells and required for tumor expansion (Liberti &
Locasale, 2016). Healthy cells within an oxygen rich environment will conduct aerobic
glycolysis and undergo oxidative phosphorylation to produce high levels of ATP. However, in
this metabolic phenomenon cancer cells take in exorbitant amounts of glucose and process it via
the same mechanism required for anaerobic glycolysis regardless of oxygen sufficiency.
Although in the context of cancer this aberrant metabolic process is referred to as aerobic, similar
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to anaerobic metabolism, it results in the production of lactate and minimal amounts of ATP. The
Warburg Effect is a pro-tumor mechanism, but its impacts are believed to be combated by
increased AMPK which exerts anti-tumor properties in cancer models through reversal of the
Warberg effect (Faubert et al., 2013). The Ketogenic diet has also been studied in breast cancer
patients and found to successfully discourage the pro-tumor effects of this metabolic shift by
balancing insulin spikes and reducing glucose levels (Khodabakhshi et al., 2021). However, the
ketogenic diet is not always sustainable for cancer patients or those wishing to utilize this eating
pattern for its insulin stabilizing benefits.
Furthermore, physical activity requires muscle contraction which increases the energetic
demands on the mitochondria within myofibrils. Similar to the function of BBR, Metformin, and
the ketogenic diet, it has been previously demonstrated that the energy consumed by this
contraction process skews ATP/AMP ratios effectively mimicking cellular fasting mechanisms
that upregulate the AMPK pathway, leading to reduced cell proliferation, and decreased insulin
levels(Drake et al., 2021). Indeed, reduction in cell proliferation is beneficial for slowing
neoplastic evading disease states such as cancer, which places exercise at the forefront of
promising cancer treatment and rehabilitation interventions.
Physical Activity and Cancer in the Immune System
A phenomenon known as the “inverted J” is a term used to describe immune function
under the influence of consistent moderate exercise (Gustafson et al., 2017). The inverted J
hypothesis suggests that too little, or too much physical activity may lead to lowered immune
function and even immune suppression, such as in the case of overtraining. Furthermore, studies
suggest exercise immune stimulating properties may relate to its ability to increase insulin
sensitivity (McTiernan, 2008) However, one exception is found in aging populations. Older
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populations experience a decrease in the benefits of exercise by an observed reduction in the
number of circulating post exercise lymphocytes as well as a shortening in the duration of their
presence within peripheral blood (Freidenreich & Volek, 2012). As the effects of exercise begin
to fade with age, additional supplementary interventions with potential anti-aging or life
extending properties, such as BBR, become of the utmost importance.
Consistent physical activity has also been proven to decrease the activity of MDSC’s.
Exercise has been found to combat the rate of cancer growth by reducing circulating total MDSC
count (Garritson et al., 2020). A recent study explored the impact of physical activity on the
immune function of a 4T1 murine breast cancer model and found that consistent wheel running,
over a 10-week period significantly decreased MDSC infiltration in the spleen, blood and tumor.
However, no reduction in tumor size was observed. Furthermore, a non- significant reduction in
metastasis of breast cancer to the lungs was observed in wheel run animals (Garritson et al.,
2020).
MDSC’s also promote suppression of anti-tumor immune function and cancer
development through reduction of CD4+ Th cells and by increasing production of Tregs through
secretion TGF-β1 (Veglia et al., 2018). Garritson et al., suggests that treatments which decrease
the activity and/or presence of MDSC’s will increase therapeutic outcomes for patients with any
form of breast cancer (Garritson et al., 2020).
Breast Cancer in the Context of Berberine
and Physical Activity
Due to its vast metabolic effects, BBR has been studied in the context of many cancers
such as esophageal cancer, nasopharyngeal carcinoma, GI cancers, and within cancer cell lines
such as HELA cells, and 4T1 mammary carcinoma (Iizuka et al., 2000; Kim et al., 2010; W. Ma
et al., 2020; Tang et al., 2009). It is estimated that 2/3 of all breast cancer cases could be
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attributed to insufficient physical activity and obesity—suggesting insulin resistance may be a
factor in development of neoplastic disease. McTiernan states that women who engage in
moderate-intensity physical activity for 3-4 hours/week experience a 30-40% reduction in breast
cancer as compared to sedentary females (McTiernan, 2008). Moderate physical activity, such as
brisk walking was found to significantly decrease breast cancer risk in women who engaged in
this type of physical activity for approximately 2.5-7 hours per week as compared to sedentary
women (McTiernan et al., 2003).
For many disease states and health conditions, exercise is a common standard of care
with many known physiological benefits. IL-6 is known to be secreted from breast cancer tissues
and is associated with poor prognosis. IL-6 is a pleiotropic cytokine that can function as both a
pro and anti-inflammatory agent. In the cancer environment IL-6 promotes inflammation and is
thought to play a role in tumor development by increasing angiogenesis as well as cellular
adhesion and tumor metastasis through activation of Rho, a protein known to stimulate cell
growth and migration (Ravishankaran & Karunanithi, 2011). IL-6 is also an indicator of breast
cancer progression and appears to increase in expression as the stage of cancer severity increases
(Ravishankaran & Karunanithi, 2011). Interestingly, IL-6 is also released from contracting
muscles as a myokine. As a myokine IL-6 exemplifies favorable glucose regulation outcomes in
healthy animals (Chow et al., 2022). One aspect of its glucose regulatory function stem from its
ability to increase insulin secretion from the pancreas which could have a negative effect on
cancer (Chow et al., 2022). However, as a myokine, IL-6 is also found to mobilize natural killer
cells which have an anti-tumor impact within the immune system (Chow et al., 2022).
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Berberine and Immune Activity
Increasing casual and voluntary consumption of BBR makes the impact of orally
administered BBR on immune activity of great interest. One way to determine BBR’s influence
on immune function is to assess T-cell activity. CD4+ helper T cells and their cytotoxic
counterparts CD8+ T-cells are vital within the immune system for protection against a host of
pathogenic factors such as viruses and cancer. A recent study conducted by Vita et al. found
cause for concern regarding the prophylactic use of BBR and possible immunosuppressive
properties in T cell populations (Vita et al., 2021). Specifically, BBR’s anti-inflammatory
function can be in part linked to suppression of effector CD4+ Th cells which directly reduces B
cell autoantibody production. Overall, this suggests that consumption of BBR may reduce the Th
cell’s capacity to provide the help needed for B cell autoantibody production lowering overall
immune response which is a function akin to some Rheumatoid Arthritis (RA) pharmaceuticals
(Vita et al., 2021). The same study found that Tregs also appear to be impacted by BBR
consumption with a higher overall proportion of FOXP3+ CD4+ Treg than FOXP3-CD4+ in BBR
treated groups as compared to PBS controls (Vita et al., 2021). Increased levels of Tregs and
lower Th cells contribute to an anti-inflammatory environment, which may be helpful in the case
of autoimmunity but potentially harmful for cancer patients.
Immune Cell Activation
When the effector T cells listed previously are activated via antigen specific binding, they
produce the transcription factor NUR77, also known as NR4A1 of the NR4A human nuclear
hormone receptor family. Coded by the gene NR4A, the presence of this transcription factor
allows discrimination between T cells by ruling out those that have been activated by the
inflammatory milieu and thus do not produce NUR77 and T cells that are actively engaged in the

14
immune response as a result of antigen presentation (Ashouri & Weiss, 2017; Wyss et al., 2016).
CD69 is also commonly used as an extracellular marker of T cell activation, however it does not
distinguish between T cell activation based on antigen specific involvement and thus is not as
precise of a measure of immune activation (Ashouri & Weiss, 2017). Higher levels of NUR77
expression in the cytosol correspond to a greater level of TCR stimulation. However, Nur77
production in the presence of BBR is not well studied. Specific T cell activity can be assessed by
staining for the transcription factor NUR77 (NR4A1 of the NR4A human nuclear hormone
receptor family).
Study Rationale
The ever-growing popularity of BBR, a potent and biologically active plant-derived
compound, is a cause for concern. The lack of human clinical trials, or studies that define its
biological effects means that consumers are unaware of potential consequences, and thus assume
lopsided, risk free, benefit of this compound. This study aims to begin to clarify the biological
effects of BBR in preclinical models.
It is important to note that very little research has been conducted connecting the dots
between the possible cooperative effects of berberine and exercise in the context of cancer. The
rising prevalence of both cancer and autoimmunity begs urgent need for additional research.
Medical practitioners, the supplement industry, as well as the food production field would
benefit from understanding the impact this compound may have on the immune system.
Moreover, understanding BBR’s immunological impact within the body, specifically in the
context of cancer paired with physical activity, may inform practitioners of evidence-based uses
for this compound. As stated before, the purpose of this study is to determine if oral consumption
of BBR when paired with physical activity will increase T lymphocyte presence and activation
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status while decreasing the presence of myeloid-derived suppressor cells (MDSC) within the
tumor microenvironment, spleen, bone marrow, and blood of both a healthy population of
immunocompetent BALB/c mice and a BALB/c 4T1 mammary carcinoma model.
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CHAPTER III
METHODOLOGY
Materials and Protocol Models
Animal Care
Female BALB/c mice (n=53) were housed in a temperature-controlled facility running on
a 12:12 (6am-6pm) light dark cycle. Mice were housed in separate cages, fed standard chow and
had access to water ad libitum. All procedures were performed in accordance with the University
of Northern Colorado’s Institutional Animal Care and Use Committee protocol 2005C-NP-M-23
and protocol 1511CE-RM-RH-18 as well as the animal welfare act guidelines.
Berberine Supplementation
Voluntary, oral BBR supplementation was achieved by suspending BBR hydrochloride
(purity > 98%; Sigma-Aldrich, St. Louis, MO, USA) into a berberine gummy made of an 8%
gelatin solution containing 2% sucralose solution (L. Zhang, 2021). Sucralose is a non-nutritive
sweetener chosen for its sweet flavor without increasing blood glucose levels upon consumption,
therefore preventing promotion of neoplasm due to increased insulin levels. Mice are inherently
neophobic, so a training period was necessary to desensitize the mice to the BBR gummy as well
as a small serving platter. Mice were fasted overnight before a vehicle gummy/platter was placed
in their cage. Mice were returned to their normal feeding schedule and a second vehicle jelly was
administered during the same time of day. After the training period, mice consumed 1 BBR
gummy (4.06 mg BBR) within 30 seconds of placing the gummy in their cage. This ensured the
peak concentration of BBR entering their system and emulated oral human consumption. Past
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studies found that a dose of 145 mg/kg of BBR administered via gavage to BALB/c was the most
effective in decreasing tumor size of tumor bearing mice (W. Ma et al., 2020). Mice typically eat
during their active dark cycle, thus, BBR was administered five days per week ten minutes
before the beginning of the dark cycle on a serving platter to prevent contamination with bedding
or excrement (figure 1).
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Figure 1
Study Design and Interventions

A

.

B

Note. This figure demonstrates an overview of study methods. All mice were fed either a BBR
gummy (sucralose vehicle) or a sucralose control gummy (A,B). Mice were randomly assigned
to a wheel running group or a sedentary group. One cohort of Balb/c mice were inoculated with
4T1 cells expressing tdT RFP mammary carcinoma cells on week 6 of the study (A). Spleen,
blood, bone marrow, lungs and tumor were harvested on day 70 which fell on week 4 after 4T1
inoculation. Tissue was processed, stained, and analyzed via flow cytometry.
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Exercise Wheel Run Model
Exercise volume was assessed by subjecting mice to a 10-week endurance voluntary
exercise wheel run protocol. This model is considered the most common animal research
physical activity protocol and mimics endurance training in humans (Manzanares et al., 2019).
Mice 6-8 weeks of age were randomly assigned to one of 8 control and intervention groups
(Table 1). Exercise mice were provided with a cage mounted running wheel (11.5cm diameter)
for the duration of the study and non-exercise mice were restricted to normal cage activity.
Running volume was monitored utilizing magnetic probes that tracked wheel revolutions every
15 seconds through Vital View data acquisition system (MiniMitter, Bend, OR).
Table 1
Outline of Intervention and Control Groups, Descriptive Abbreviations, and Sample Size
Group

Control

Berberine

Exercise

Berberine
& Exercise

Cancer

Berberine &
Cancer

Exercise &
Cancer

Abbreviation

Cont.

BBR

EX

BBR+EX

4T1

BBR+4T1

EX+4T1

Sample
Size

N=3

N=3

N=4

N=3

N=8

N=8

N=8

Berberine,
Exercise &
Cancer
BBR+EX+4T1

N=8
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Fluorescent 4T1 Tumor Inoculation and Measurement
Cell Growth and Stable Plasmid Insertion
Fluorescent Model
4T1 mammary carcinoma cells were originally purchased from ATCC (Manassas, VA)
and cultured in RPMI 1640 (ThermoFisher) supplemented with 1% pen/strep, 2mM LGlutamine, 1mM Sodium Pyruvate, 10mM HEPES, 0.05mM β-mercaptoethanol, and 10% (by
volume) fetal bovine serum (FBS). To achieve syngeneic tumor growth BALB/c female mice
(The Jackson Laboratory, Bar Harbor, ME) were selected for injection with 4T1 tdTomato
expressing cells. Cells containing the pcDNA 3.1 tdT plasmid (figure 3) successfully produce a
fluorescent protein that, unlike other luminescent models, do not require a complementary
substrate for activation (Patel et al., 2010). In this model synthetic firefly luciferase is paired with
a protein known as Tandem Tomato (tdTomato) which emits photons that appear red when
stimulated with a blue-yellow laser during flow cytometry or fluorescence microscopy (figure 2).
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Figure 2
tdT Expressing 4T1 Cells

Note. This figure demonstrates the fluorescence intensity of cells tranfected with the tdT
plasmid. Cells were analyzed utilizing fluorescent microscopy with a blue-yellow laser.
Inoculation and Tumor Progression
The plasmid insert also expresses neomycin antibiotic resistance, allowing tdT containing
cells to be cultured under antibiotic selection (Lith et al., 2020). RPMI cell growth media was
used to culture 4T1/tdT plasmid containing cells and was changed every three to four days.
Antibiotic selection was achieved by the addition of 30L (50mg/mL) of neomycin G418
(Sigma), added on day two after each medium replacement. On the 6th week of the study,
animals were inoculated with 10^5 4T1 mammary carcinoma cells containing the pcDNA 3.1
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tdT plasmid. G418-Neomycin was removed a day before inoculation and cells were rinsed to
remove any lingering antibiotic and provided fresh C-RPMI. On the day of inoculation, media
was removed, and cells were rinsed again and suspended in 100 µL HBSS (Ca2+/Mg2+ free,
ThermoFisher) before injection with a 25-gauge syringe needle into the nipple of the right, fourth
mammary fat pad. Mice were monitored for any signs of infection around the site of injection.
Upon euthanasia, at day 28, tumor mass was obtained, and tumor volume was calculated using
the equation π/6 × width × length^2 where length refers to the area of largest diameter and width
was found by measuring 90 degrees from length. Length and width were assessed via digital
calipers.
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Figure 3
Red Fluorescent Protein Addition to the Genome of 4T1 Mammary Carcinoma Cells

Note. This figure represents the pcDNA 3.1 Tdt. Plasmid Map and was adapted from “TdTomato
and EGFP identification in histological sections: insight and alternatives,” by L. Morris, C.
Klanke, S. Lang, F-Y. Lim, & T. Crombleholme,. 2010. Biotechnic & Histochemistry, 85(6),
379–387. https://doi.org/10.3109/10520290903504753.
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Euthanasia
On week 10 mice were euthanized via CO2 asphyxiation, and tissues were harvested.
Running wheels were removed from the cage 24 hours before euthanasia, and a feces sample was
collected directly before euthanasia for PCR analysis.
Tissue Preparation and Analysis
Aortic puncture was utilized for collection of blood from the chest cavity and 100 µL of
heparin was infused locally to prevent clotting. Blood was then incubated with 2 mL ACK lysis
buffer for 3-5 minutes, centrifuged at 0.2 RCF for 5-6 minutes before a second incubation with
ACK lysis buffer to remove any remaining erythrocytes. Finally, blood was centrifuged at 0.2 xg
for 5-6 before resuspension in 1mL of 1X HBSS and placed on ice for staining. Whole spleens
were weighed and dissociated in 500 µL 1X HBSS through pulverization by a rubber policeman.
The spleens of tumor bearing mice were weighed whole and then divided in half for dissociation.
Lungs were harvested and mechanically homogenized using a cell dissociation sieve fitted with a
100 µm mesh screen. Tumors were extracted and weighed following the removal of extraneous
tissue before undergoing mechanical homogenization via the same method used for lung tissue.
To achieve a single cell suspension lung and tumor pulp were re-suspended in HBSS and
enzymatically digested in Type IV collagenase (2 mg/mL) and DNase (0.1 mg/mL;
Worthington) on a platform rocker for 45minutes at 37 degrees Celsius at 225rmp. Remaining
erythrocytes from various tissues were cleared utilizing ACK lysis buffer (Quality Biological).
Bone marrow was isolated from the femur and tibia of both hind legs. All tissues were strained
through a 100 µm cell strainer (VWR) in preparation for Fc blocking and antibody staining.
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Cellular Permeabilization, Flow Cytometry
and Antibody Staining
Spleen, blood, lung, and tumor cell suspensions were aliquoted to appropriate cell
concentrations (~106 cells/mL) for staining. Cells were Fc blocked (101302) on ice for 10
minutes prior to staining for intracellular and extracellular markers. All cells were stained for
extracellular surface markers in flow cytometry buffer containing 0.5% BSA in Ca2+/Mg2+ free
1X Dulbecco’s PBS (ThermoFisher). Following extracellular staining, approximately half of all
cells were set aside for intracellular permeabilization by the True-Nuclear Transcription Factor
Buffer set (Biolegend) before staining for intracellular markers. Unless otherwise indicated, flow
reagents and antibodies were sourced from Biolegend (San Diego, Ca). Samples were
fluorescently analyzed on the Attune NxT Cytometer (ThermoFisher); and raw data were
analyzed using Flowjo v10. Antibodies used to define cell types and biomarker expressions in
these studies are outlined in Table 2.
Table 2
Biomarker Profiles, Antibody Catalog Numbers and Supplies
Cell Type
Lot/Cat Number

Supplier

MDSC (CD11b+Ly6G+Ly-6C+)

147001

BioLegend

CD3+

b346120/100222

BioLegend

CD4+

b266324/100438

BioLegend

CD8+

2162149/12-5965-82

BioLegend

Nur77+

2162149/12-5965-82

ThermoFisher

FoxP3+

b331607/126406

BioLegend
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Gating for Flow Cytometry
Initial forward and side scatter gating was used to exclude any possible cellular debris.
Following acquisition, each sample is plotted with forward-scatter (FSC) (which measures size
of each event) vs side-scatter (SSC) (which measures the internal complexity of each event).
Next, doublet discrimination was performed to exclude any clumped cells. Remaining cells were
plotted based on respective extracellular or intracellular markers (see table 2). Unstained controls
were used to exclude background fluoresce.
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Figure 4
Extracellular and Intracellular Gating Strategy Represented by Spleen Tissue

Note. Cellular debris were gated out and single cells excluded. CD3+, CD4+, FOXP3+, CD8+, and NUR77 expression are all represented within this gating strategy. CD4+ and CD8+
are expressed as frequency of the CD3+ gate.
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Figure 5
Lung Fluorescence Gating Strategy

Note. For all samples cellular debris were gated out and doublet discrimination was performed. Tumor bearing lungs (A) showed increased red fluorescence as compared to nontumor bearing lungs (B).
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Figure 6
MDSC Gating Strategy

Note. Spleen samples from tumor bearing animal showing total CD11b frequency as well as gating for Ly6C -/LY6C+ and Ly6G-/Ly6G+.
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Statistical Analysis
One-way ANOVAs utilizing Tukey’s post hoc comparison method of locating significant
pairwise variations were run for each tissue type to compare the means between each group. Pvalues that fell within p < 0.05 were considered representative of significant variation within
immune marker frequency. All statistical analyses were conducted in Prism version 9.4.1
(GraphPad). Unless otherwise indicated all samples are reported as means ± SEM.
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CHAPTER IV
RESULTS
Impacts of Berberine Supplementation on Cancer
Progression and Physical Activity
The primary purpose of this study was to investigate immune cell accumulation within
tumor-bearing and healthy host subjects after voluntary oral BBR supplementation and/or
voluntary physical activity. A secondary purpose of this study was to measure wheel running
volume in animal subjects supplemented with voluntary oral BBR. The final purpose of this
study was to assess the impact of voluntary oral BBR supplementation with or without physical
activity on 4T1 metastasis to the lungs. We hypothesized that oral consumption of BBR, when
paired with physical activity, would increase T lymphocyte presence and activation status while
decreasing the presence of MDSC’s within the tumor microenvironment, spleen, bone marrow,
and blood of both a healthy population of immunocompetent BALB/c mice and a BALB/c 4T1
mammary carcinoma model. We also suspected that BBR would have a negative impact on
voluntary exercise volume, and that the impact of voluntary oral BBR supplementation with or
without physical activity would decrease metastasis to the lungs of mice inflicted with 4T1
mammary carcinoma.
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Physical Activity and Wheel Running Volume
Mice were randomly assigned to a control non-tumor-bearing-sedentary group (Control
n=3), a wheel run group (EX, n=3), a BBR wheel run group (BBR+EX, n=3) a control-4T1tumor-bearing-sedentary group (4T1, n=8), or a tumor bearing, BBR, wheel run group
(BBR+EX+4T1, n=8). Mice were given approximately 7 days to adjust to their new environment
before running data were collected. Wheel running data were recorded at 15 second intervals and
compiled into 2-week averages based on treatment groups (figures 7A and 7B). Non-tumor
bearing animals not treated with BBR exhibit a relatively normal wheel running pattern with a
steady decrease after the first few weeks of wheel access. BBR+EX animals exhibited a slightly
lower initial exercise volume but did not experience the same weekly decrease as animals not
receiving BBR treatment. The distance run by each of the two treatment groups intersected at
weeks 5-6 with BBR averaging at 9.1 km/day ± 0.5 SEM and BBR+EX with a mean distance of
9.2 km/day ± 0.2 SEM. The following weeks resulted in a steady decline on average in the EX
group whereas the BBR+EX group exhibited a minimal decrease in km run. Comparatively,
between weeks 5-6 and weeks 9-10 the exercise group distance had reduced by 3km and the
BBR+EX group had only reduced by approximately 1km.
Within the tumor bearing groups very little change was noted in both the BBR and nonBBR supplemented groups exhibiting similar patterns of early increase in distance ran before
subsequent decrease in progression over the following weeks. The only notable divergence was
found in weeks 3-4 where the mean running distance of the BBR+EX+4T1 group (10.2km/day ±
0.3) did not exhibit a marked increase in distance run like the 4T1+EX group, which exhibited a
temporary increase (figure 7B). When the BBR+EX group was compared to the BBR+EX+4T1,
and the EX-group compared to the EX+4T1 group, similar trends were observed. In the animals
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supplemented with BBR an overall change from week one to week ten showed an approximate
total decrease of 2.1 km in the BBR+EX group and 3.3 km in the BBR+EX+4T1 group. In the
EX and EX+4T1 groups a greater overall decrease was observed at 6.5 km and 4.2 km
respectively.
Figure 7
Wheel Running Volume in BALB/c 4T1 Tumor-Bearing Female Mice
Non-Tumor Bearing Animals
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Note. Average wheel run volume in km/day over a 70-day period (divided into 2-week time
increments). Non-tumor bearing animals (A) represented separately from tumor-bearing groups
(B). Time points represented as mean ± SEM.
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Metastasis to the Lungs
To assess metastasis of mammary carcinoma with or without EX and BBR we utilized a
4T1 Mammary Carcinoma cell line that we enhanced with the monomeric tandem dimer (Td)
Tomato fluorescent protein. This method has been previously used to tag specific cells for invivo observations in mice (Takahashi et al., 2015). However, to our knowledge it has not been
utilized to assess cancer metastasis. Tdtomato 4T1 cells produce a red protein that is fluorescent
in the YL1-A channel and possesses an extremely bright emission wavelength of 581nm.
Between treatment groups no significant change was observed from baseline control,
non-tumor bearing animal (figure 8). However, a significant increase (**p<0.01) in MFI between
the non-tumor bearing control lungs and tumor bearing lungs was observed (figure 8).
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Figure 8
Fluorescence Intensity Within the Lungs of Tumor Bearing BALB/c Mice at 4 Weeks Post
Injection with 4T1 Mammary Carcinoma

Note. Lung Fluorescence in tumor bearing animals as compared to the lung fluorescence of a
non-tumor bearing animal (ctrl). Fluoresce measured as mean fluorescence intensity (MIF)
*p<0.05, **p<0.01, ***p<0.001.
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Tumor and Spleen Mass
Whole tumors and spleens were extracted from each subject and mass was collected
(mg). Fold change was calculated for the spleens of each group by dividing the mass of
individual spleens in each of the respective groups by the average mass of the spleens from nontumor bearing animals. The same method was utilized for calculating fold change of tumor mass,
with the exception of a tumor-bearing animal that had not been assigned to either the BBR or
physical activity groups functioning as the control devisor (figure 9). The most notable change is
seen in the BBR+4T1 groups spleen when compared to the same group's tumor mass. The
BBR+4T1 group (n=8) exhibited the smallest fold change in spleen mass, but the largest fold
change in tumor mass. The BBR+EX+4T1 spleen (n=8) experienced the largest fold change in
splenic mass but a negative fold change compared to the sedentary 4T1 control group tumor
mass.
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Figure 9
Comparative Spleen and Tumor Mass Between Treatment Groups

Note. Spleen mass, represented as fold change over respective non tumor control ± SEM. Tumor
mass, represented in fold change from 4T1 no treatment control ± SEM *p<0.05, **p<0.01.

38
Immune Markers
CD11B Leukocytic
Immune Populations
CD11B is a marker expressed on Leukocytic cells such as monocytes, natural killer cells,
and granulocytes. Significant expansion of CD11B was seen in the spleen and bone marrow
between a control non-tumor bearing animal and a tumor bearing animals. However, no
treatment effect was seen within the control and tumor bearing groups. Across most tissues
(figures 10 A and D), on average there was a trend suggesting slight non-significant elevation in
CD11B counts within the BBR+4T1 group.
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Figure 10
Accumulation of Total CD11B Count Across All Tissue Samples
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Note. All non-tumor bearing samples were compared to non-tumor bearing samples along with
comparisons within the tumor bearing samples and control groups. No significant intervention
specific change was seen within the tumor bearing group. P values numerically represented to
show samples that are nearing significance. *p<0.05, **p<0.01.
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Myeloid-Derived Suppressor Cell
Immune Subsets
CD11B+LY6C+ and LY6G+ Myeloid-derived subsets were analyzed within each tissue of
each mouse. Within the LY6C+ subsets minimal variations were observed not only across
treatment groups but also between tumor bearing and non-tumor bearing animals. On average the
blood showed an observable increase in circulating LY6C+ populations within tumor bearing
animals (figure 11B). The inverse was true within the bone marrow with an observable increase
in the LY6C+ non-tumor bearing population (figure 11D).
LY6G+ MDSC’s exhibited significant increases across the tumor bearing group as
compared to non-tumor bearing groups in all tissues (figure 12). However, within the tumor
bearing and non-tumor bearing groups no statistically significant treatment specific effects were
observed. Exercised animals in the non-tumor bearing bone marrow group were an exception to
this observation exhibiting a significant increase when compared to the bone marrow of all other
non-tumor bearing animals.
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Figure 11
LY6C MDSC Cell Counts Represented Across All Tissues

Note. Very minimal significant change in LY6C+ subsets were observed across intervention
groups.
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Figure 12
LY6G MDSC Cell Counts Represented Across All Tissues
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Note. Very minimal significant change in LY6G+ subsets were observed across intervention
groups. However, there was a significant increase in LY6G subsets across most tissues between
the non-tumor bearing and the tumor bearing animals. *p<0.05, **p<0.01, ***p<0.001 and
****p<0.0001.
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CD3+ and CD4+ T Effector Subsets
Various CD3+ T cell phenotypes were assessed in the spleen, blood, bone marrow, and
tumor of each intervention and control group. On week 10, 28 days post tumor inoculation the
change in frequency of all CD4+ cells remained relatively moderate across the tissue types with
no statistically relevant findings suggesting a lack of intervention specific suppression and/or
stimulation of Th cells (figures 13 through 18). However, some CD3+ intervention specific
variance was noted between control and intervention groups. We compared the spleens of 4T1
sedentary controls to the spleen of tumor and non-tumor bearing EX mice resulting in a
significant increase (p <0.05) in CD3+ cells residing in the spleens of non-tumor bearing EX
mice (figure 13A). The same non-significant general trend was noted in the spleens of exercised
tumor bearing animals. Within the same tissue, non-significant CD3+ increase was also noted in
both the BBR+4T1 and EX+4T1 groups when compared to both tumor bearing and non-tumor
bearing (healthy) controls (figure 13 A and B).
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Figure 13
Frequency of Lymphocytes Within the Spleen of Tumor and Non-Tumor Bearing BALB/c Mice

Note. Lymphocytes isolated from splenic tissue in non-tumor bearing (A) and tumor bearing (B)
animals. The presence of resident CD3+, CD8+, CD4+ and FOXP3+ lymphocytes ls is
represented as frequency (%) ± SEM; n= 3-8 mice per group. *p<0.05.
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Figure 14
Frequency of Lymphocytes Within Tumors of BALB/c Mice

A

C

B

D

Note. 4T1 mammary carcinoma cells (105 ) were injected into the right mammary gland of
BALB/c mice and harvested after 28 days. The presence of CD3+, CD8+, CD4+ and FOXP3+
lymphocytes isolated from tumor bearing animals is represented as frequency (%) ± SEM; n= 38 mice per group. *p<0.05, **p<0.01.
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Resident and Circulating Cytotoxic
T Lymphocytes
CD8+ T lymphocytes were found to significantly increase within the blood of tumor
bearing mice (figure 15B). This increase was observed specifically in tumor bearing wheel run
mice when compared to blood taken from sedentary tumor bearing controls (p<0.01).
Interestingly, when BBR was paired with wheel running in tumor bearing mice (BBR+EX+4T1),
frequency of CD8+ T cells circulating in the blood were found to decrease significantly (p<0.05).
The most significant variation across tissues was observed in CD4+ FOXP3+ subsets
(figure 16 and 17) with the lungs exemplifying the greatest amount of variation.
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Figure 15
Frequency of Lymphocytes Within the Blood of Tumor and Non-Tumor Bearing BALB/c Mice

Note. Lymphocytes isolated from blood obtained via cardiac puncture in non-tumor bearing (A)
and tumor bearing (B) animals. The presence of circulating CD3+, CD8+, CD4+ and FOXP3+
lymphocytes is represented as frequency (%) ± SEM; n= 3-8 mice per group. *p<0.05.
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Tissue Specific Infiltration of CD4+CD24+
FoxP3+ T-regulatory Cells
EX+4T1 mice were observed to possess the highest frequency of tumor resident Tregs.
Intriguingly, sedentary BBR+4T1 mice had significantly less Tregs within tumors than EX+4T1
mice (p<0.05) and when BBR and physical activity were administered together to tumor bearing
mice (BBR+EX+4T1) the frequency of tumor resident Tregs decreased noticeably (figure 14). The
tumors of EX mice were also approaching a significantly (p=0.054) greater number of Tregs than
those found in sedentary 4T1 mice. Our studies found circulating Tregs at the highest
concentration in the blood of sedentary 4T1 and non-tumor bearing EX animals (mean of 1.0% ±
SD of all circulating CD4+ cells). But this variation between groups was not found to be a
significant increase when compared to a healthy or tumor bearing control respectively (fig 14).
The highest frequency of Tregs was found within the lungs of control non-tumor bearing animals
making up 3.0% ± SD of all CD4+ expressing cells (figure 16).
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Figure 16
Frequency of Lymphocytes Within the Lung of Tumor and Non-Tumor Bearing BALB/c Mice
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Note. Lymphocytes isolated from the lung via mechanical and enzymatic tissue dissociation in
non-tumor bearing (A) and tumor bearing (B) animals. The presence of tissue resident CD3+,
CD8+, CD4+ and FOXP3+ lymphocytes is represented as frequency (%) ± SEM; n= 3-8 mice per
group. *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001.

50
Figure 17
FOXP3 Specific Variation Within Various Tissues

Note. Significant variation between CD4+CD24+Treg+ lymphocyte frequencies isolated from nontumor bearing lung (A), tumor bearing lung (B), Tumor bearing spleen (C) and Tumor (D). The
presence of tissue resident FOXP3+ cells is represented as % of CD4+ frequency ± SEM; n= 3-8
mice per group. *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001.
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Activation Status (Nur77)
Activation status was assessed for CD4+, CD8+, and FOXP3+ lymphocytes in the spleen,
tumor, lungs and blood, of all treatment and control groups (Figures 18 and 19). Modest
variation was seen between groups with a notably higher expression of NUR77 in the tumor
bearing groups than in the non-tumor bearing group comparatively (Figure 18). Statistical
analysis utilizing one way ANOVA’s and Tukey’s multiple comparisons test suggested no
significant variation between groups (figure 18).
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Figure 18
Nurr77 Expression Within the Spleen and Tumor of Each Control and Intervention Group

Note. Activation status measured in Mean fluorescence intensity (MFI) ± SEM. Non-significant
treatment effects can be observed throughout each immune marker subset. P values represented
above bracket.
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Figure 19
Nurr77 expression within the blood and lung of each control and intervention group

Note. Activation status measured in Mean fluorescence intensity (MFI) ± SEM. Non-significant
treatment effects can be observed throughout each immune marker subset. P values represented
above brackets.
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CHAPTER V
DISCUSSION AND CONCLUSIONS
Discussion
This study was one of the first to assess the combined impact of BBR and physical
activity on immunological impact within a breast cancer model. It is also one of the first studies
to explore exercise volume under BBR supplementation in tumor bearing and/or healthy
subjects. The purpose of this study revolved around elucidation of the impact oral consumption
of BBR when paired with physical activity may have on increasing T lymphocyte presence and
activation status while decreasing the presence of MDSC’s within the tumor microenvironment,
spleen, bone marrow, and blood of both a healthy population of immunocompetent BALB/c
mice and a BALB/c 4T1 mammary carcinoma model.
With increasing accessibility and utilization of BBR as an over-the-counter nutraceutical,
as well as an herbal intervention with growing popularity in the medical and health realms it is
important to understand the impact BBR may have on the immune system as well as how it
might impact aspects of daily living such as physical activity. Physical activity has been
extensively studied in the context of breast cancer, however BBR and its immunomodulatory
effects are not as widely understood. The impact BBR may have on physical activity volume is
of special interest to both healthy and diseased populations, as well as any utility it may have in
prevention or co-treatment of breast cancer.
To evaluate overall immune function, both presence of specific T lymphocytes as well as
activation status were assessed. Information on total CD3+ T lymphocyte frequency along with

55
CD8+ Cytotoxic, CD4+ T-helper, and CD4+CD24+FOXP3+ T-regulatory frequency and activation
status in the blood, spleen, and lung of healthy and tumor bearing animals was gathered. We
aimed to monitor metastasis to the lungs of tumor bearing animals in BBR and/or physical
activity treatment groups while also considering the impact these treatments may have on spleen
and tumor growth in both healthy and tumor bearing subjects.
Berberine May Impact Physical
Activity and Wheel
Running Volume
A marked decrease in wheel run volume could be seen in the weeks following 4T1
injection which may suggest discomfort when running from the developing tumor mass, or
systemic inflammation leading to reduced energy levels. Normal healthy mice will run
approximately 4-20 km/day with the greatest distance run in the first few weeks of being housed
with a wheel and decreasing distances each subsequent week (Manzanares et al., 2019; Turner et
al., 2005). Our data generally replicated this trend with some exceptions to this rule within the
non-tumor bearing BBR supplemented groups. These subjects, on average, maintained wheel run
volume than non-BBR treated non-tumor bearing mice. This phenomenon is noteworthy due to
the fact that BBR is thought to function in a similar manner to metformin—a drug that is well
known to decrease exercise volume in patients (Wong et al., 2012). It thus may be assumed that
BBR would follow a similar pattern. However, our data suggested BBR may have a stabilizing
effect on wheel running volume in mice. This possible conclusion will require further
investigation as to whether BBR may have a metabolically favorable effect on exercise volume,
over time, within a healthy population.
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Metastasis to the Lungs
Fluorescent and luminescent cancer models have been used in the past to track tumor
metastasis. However, to our knowledge, they have never been used in conjunction with BBR
treatments. Luciferase expressing cancer cell lines are one example of a luminescent cell model.
The genome of 4T1 mammary carcinoma cells may be manipulated to express fluorescent
luciferase proteins, or the same cell line may be edited to transcribe other fluorescent proteins
within their genome, such as TdTomato. 4T1 Mammary Carcinoma cell lines have been
commonly used to assess metastasis to the lungs of mice (Takahashi et al., 2015). Dyes have also
been used to differentiate healthy lung cells from infiltrating tumor cells, but the accuracy of this
method is less than desirable (Garritson et al., 2020).
For the purpose of tracking metastasis to the lungs, red fluorescent protein (RFP)
expressing cells were injected into the tumor groups. 4T1 cells have a special affinity for the
lungs, which is why this specific tissue was chosen to represent metastatic variance among
intervention groups (Pulaski & Ostrand-Rosenberg, 1998). Between treatment groups no
significant change was observed that would suggest treatment specific effects.
However, a significant increase in MFI between the non-tumor bearing control lungs and
tumor bearing lungs regardless of intervention was observed (figure 8). This suggests that the
fluorescent 4T1 cells did indeed migrate to the lungs with the tdT protein intact. However, it
appears that metastasis of the red 4T1’s is not impacted by BBR, physical activity or a
combination of the two. Alternatively, a greater number of 4T1 cells may have spread to the
lungs but fluorescence was not observed because they had discarded the RFP from their genome
through mutation.
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Spleen and Tumor Mass
In ancient times BBR was utilized as a treatment for splenomegaly. In the modern era
BBR is still claimed to treat this condition but there is very little evidence supporting these
claims.
The data collected from the spleen and tumors of tumor bearing vs healthy mice revealed
the BBR+4T1 group to exhibit the smallest fold change in spleen mass, but the largest fold
change in tumor mass (figure 9). This could indicate that BBR was suppressing extramedullary
hematopoiesis within the spleen. Extramedullary hematopoiesis is common in diseased states
such as advanced tumor progression or viral infections like Epstein Barr Virus (Yang et al.,
2020). This significant decrease in spleen mass may validate claims of BBR as an intervention
for splenomegaly. However, the associated increase in tumor mass suggests that BBR may
suppress the immune system to a point where it is not able to adequately respond to the challenge
of a growing tumor. BBR may indeed remediate some of the effects of splenomegaly, but further
research will be required to assess if the anti-inflammatory cost is too high for BBR to be utilized
as an effective anti-inflammatory treatment in cancer patients.
Overall, EX did not appear to influence spleen or tumor mass. On average spleens from
the BBR+EX+4T1 group experienced the largest fold change which resulted in less massive
tumors (figure 9). This observation begs the question if exercise and BBR together increased
immune function and extramedullary hematopoiesis through immune enhancing properties that
neither BBR nor EX possess alone. Our immune marker data suggests that a slight increase in
CD3+ lymphocytes could be in part responsible for the increased spleen mass (figure 9).
However, the lack of significant increase of other immune cell groups within the spleen may
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suggest that other non-CD3+ cells are being produced and leading to significant increase in
spleen mass variation from the control.
Myeloid-Derived Immune Populations
LY6C+LY6Glow and LY6G+LY6Clow cells are considered monocytic and granulocytic,
respectively (Höchst et al., 2015). These cells have been found to exert immunosuppressive
effects on T cell populations. MDSC’S are immature monocytic cells that arise within the body
in states of extreme inflammation, cancer, or pregnancy (Höchst et al., 2015; Youn et al., 2008).
Some studies suggest that MDSC expansion is influenced by soluble factors produced by the
tumor microenvironment (Youn et al., 2008) This would explain the well elucidated increase
seen within MDSC’s in tumor bearing animals compared to non-tumor bearing animals
(Garritson et al., 2020; Youn et al., 2008). This overall expansion of MDSC’s may also account
for splenic expansion observed within tumor bearing mice (figure 9). One observation that has
not been well elucidated is the expansion of LY6G+ MDSC’s in the spleens of tumor bearing
mice (figure 12). Our study found LY6G+ MDSC’s to be larger in size than LY6C. Thus, it leads
to the hypothesis that an expansion of LY6G+ cells would significantly increase spleen mass.
Interestingly, the spleens of the sedentary, tumor bearing animal that received BBR
supplementation were the smallest of the tumor bearing spleens (figure 12). If MDSC expansion
accounted for the additional splenic mass observed in tumor bearing spleens, we would expect
that LY6G+ MDSC expansion would increase. But this was not the case. Rather, there was a
non-significant increase in LY6G+ count within the spleen of this treatment group but the spleens
of this group were on average smaller than relative tumor bearing controls that did not receive
BBR. Another reason for the spleen size reduction within the 4T1+BBR group could be
mobilization of MDSC’s from the spleen into the blood. Within the blood of tumor bearing
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exercised animals there was a significant increase in LY6G+ cells compared to a non-tumor
bearing control, however, there was not a significant decrease in this subset from 4T1 controls.
Within the lungs of tumor bearing animals there is an increase in LY6G as well as Tregs.
Interestingly, there is an established connection between MDSC and Treg cross talk in
contributing to suppression of anti-tumor immunity (Siret et al., 2020).
This does not follow the trend of decreased total circulating and tumor resident MDSC’s
seen in other studies where exercise was found to decrease MDSC counts in the blood and spleen
of tumor bearing animals (Garritson et al., 2020). However, these studies assessed total MDSC
count at various time points and did not evaluate the specific subsets. Reduction in total MDSC
count was observed in the blood at day 16, however this trend was not maintained up to day 28
(Garritson et al., 2020). Our described study only measured MDSC counts on day 28 which may
have impacted intervention specific effects.
Lymphoid Derived Immune
Populations
Very little statistical significance was observed within Lymphoid populations across the
tissue types. This may indicate that by day 28, when mice were euthanized, BBR and EX had
reduced impact on the frequency of immune cells within a cancer population. However, the same
trend was seen within a healthy population with only minimal increase or decrease among
specific immune markers. This may suggest that BBR and exercise had minimal statistically
relevant impact. However, a generalized non-significant decrease was observed within BBR
treated CD4+ T cells across each of the tumor bearing tissue groups and the same trend was
observed within CD8+ T cells excluding a significant CD8+ increase in tumor bearing tissues.
These findings align with the discoveries of Turbitt et al., who observed a significant decrease in
CD4+ and CD8+ T cells within physically active tumor bearing mice (Turbitt et al., 2019).
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Alternatively, the lack of significance could be owing to the fact that at time of sacrifice, the
tumors had aggressively progressed, and T cell exhaustion could have played a role in decreasing
the frequency and activity of these T effector subsets. Studies suggest that CD8 + T-cells may
become exhausted within a cancer patient due to persistent antigen recognition leading to over
stimulation of the TCR and long-term activation (Kwon et al., 2022). This exhausted state leads
to progressive loss of function and proliferation lowering numbers of T effector subsets (Kwon et
al., 2022).
Wheel running appeared to have the most significant effect on CD3+ cells. A significant
increase from baseline in the spleen of wheel run non-tumor bearing animals was observed on
day 28 of the study. However, this CD3+ increase did not translate into increased CD4+ or CD8+
counts within healthy wheel run mice. This begs the question of what may be causing splenic
growth if not a T effector subset. MDSC expansion could be one answer to this question,
increased production of blood cells to meet the increased demands of tumor growth is also
theorized.
It is well understood that healthy animals will not produce high numbers of CD8+ T cells;
this means that increased CD8+ frequency within overall residential or circulating T cell numbers
may indicate an active immune response against viral infection, or cancer. Modest statistically
relevant fluctuations in frequency of circulating CD8+ T cells were found in the blood of tumor
bearing animals (figure 6). The greatest increase compared to a baseline tumor bearing control
group was seen in the EX+4T1 group. These findings align with the findings of Garritson et al.,
who observed suppression of CD3+CD8+ T cells by MDSC’s to be ameliorated within a
physically active tumor bearing population (Garritson et al., 2020).
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T Regulatory Cells in the Context of
Berberine, Physical Activity and Cancer
The airways and lungs are considered an external surface with robust innate and adaptive
defenses against a constant stream of external allergens and pathogens. In response to these
external challenges, the lungs are immunologically very active and Tregs are of vital importance
for maintaining homeostatic control and preventing excessive inflammatory responses.
Furthermore, as stated before, 4T1 cells have a specific affinity for the lungs and are a common
site for metastasis making the pulmonary space an environment rich in Tregs (Pulaski & OstrandRosenberg, 1998).
The tumor microenvironment, regardless of tissue, can evade immunosurveillance by
hijacking the function of immunosuppressive cells such as Tregs. Increased Treg function within a
tumor may foster a favorable environment for tumor growth and metastasis by effectively hiding
the neoplasm from adaptive immune response. The concept of decreasing Treg presence and
function within a tumor without dampening the overall impact of Tregs in other bodily tissues is
of the utmost value.
Intentional alteration of Treg function would revolutionize immunotherapy. Tregs are
central in the theoretical ability to manipulate immunological homeostasis within the body as
well as the tumor microenvironment (Huang et al., 2004). Our study isolated CD4+CD24+Treg+
cells by gating for FOXP3+ events within a CD4+ positive population.
In line with this concept of immunity in the lungs, the overall greatest variation in Treg
frequency could be observed in the lungs of both healthy and tumor bearing animals (figure 16).
Across the tissue types BBR and EX, when administered separately, seem to have the greatest
influence on Treg frequency (figure 17). But these interventions showed opposite impacts across
the tissue types with BBR generally decreasing Treg frequency and EX often increasing Treg
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frequency. This non-significant increase could be attributed to the fact that physical activity
increases respiration and therefore the number of foreign particles inhaled may cause an
inflammatory response.
EX+4T1 mice were also observed to possess the highest frequency of tumor resident Tregs
(figure 8D). Intriguingly, sedentary BBR+4T1 mice (figure 8D) had significantly less Tregs within
tumors than EX+4T1 mice (p <0.05) and when BBR and physical activity were administered
together within tumor bearing mice (BBR+EX+4T1) the frequency of Tregs decreased noticeably
suggesting BBR may ameliorate some of the impact of exercise on Treg accumulation within the
tumor (figure 14). BBR alone within a tumor did not appear to vary in effect from the 4T1
control group. This suggests that BBR alone may exert minimal influence on Treg infiltration into
the tumor microenvironment. However, physically active animals did see a Treg increase
approaching significance (p=0.054) of T reg infiltration into the tumor compared to Tregs in the
tumor of a sedentary 4T1 mouse (figure 14). The P value for the comparison of EX+BBR to 4T1
tumors was well over 0.05 which may confirm the idea that BBR reduces the impact of EX on
Treg infiltration into the tumor. This is an important finding to further explore because it would
allow cancer patients to experience greater immunological benefits from consistent physical
activity.
Furthermore, when physically active tumor bearing spleen Treg frequency is compared to
Treg frequency within a physically active tumor group an inverse relationship of increased
frequency within the tumor and decreased frequency within the spleen can be observed.
However, Treg function within the tumor of BBR treated mice vs non-BBR treated mice showed
a slight non-significant difference within the BBR treated mice (figure 14D). Within the spleen,
when BBR and EX were administered separately, there was a significant decrease in Treg
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frequency within the control spleen Treg numbers (figure 13). Treg function in the presence of
BBR and physical activity is conflicted, warranting more investigation to elucidate both the
frequency and function of Tregs under the influence of BBR in various tissues. These findings
again point to the suggestion that BBR may not influence immune response when taken orally by
healthy or cancer patients.
Bioavailability of Orally
Administered Berberine
It is important to note when considering the impact of BBR within the immune system
that most studies utilize findings that were derived from research methods that have exclusively
administered BBR via routes dissimilar to the oral consumption of BBR seen within the lay
public. Route of administration is an important consideration in BBR supplementation because
many sources have recognized BBR as significantly hydrophobic with an oral bioavailability of
approximately 1% (Feng et al., 2015). As is similar for many orally administered drugs (L.
Zhang et al., 2021) to be absorbed across the epithelial brush, border BBR must be first
converted via microbial metabolism into dihydroberberine. After entering the bloodstream,
dihydroberberine is oxidized back into its original form (Feng et al., 2015). The low
bioavailability and required microbial metabolism of BBR requires that more research be
conducted with orally administered BBR. The low bioavailability may also influence its
seemingly low impact on immune marker frequencies as well as activation status and tumor
metastasis.
The anti-microbial properties of BBR lead to another supposition for why very little BBR
specific significance was seen across treatment groups. As stated above, BBR requires microbial
metabolism in the gut for absorption. Within the functional medicine community, health care
practitioners often prescribe BBR cyclically, with patients consuming the compound for a few
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weeks before engaging in a short wash-out period to allow the gut microbiome to replenish.
However, if BBR was reducing microbial activity within the gut, its absorption rate over time
may have been slowed. By day 28 the anti-microbial effects of BBR could have significantly
reduced the impact that BBR had on immune markers in the later stages of tumor development
by reducing absorption rate through the intestinal epithelium. Later studies may find it
advantageous to investigate pairing a probiotic with BBR supplementation.
This study was limited by small sample sizes within control groups that may have
reduced the significance of possible variation between treatment groups. Further investigation is
warranted to confirm that BBR does indeed impact T reg infiltration into tissue specific
environments as well as any impact EX+BR may have on CD8+ frequency within the blood of
tumor bearing animals. Furthermore, it is of special interest to elucidate the possibility of BBR’s
impact on sustained long term physical activity outside of a cancer context.
Conclusions
In the presented study we hypothesized that subjects treated with this combination of
voluntary oral BBR and voluntary physical activity will have reduced MDSC counts, and
increased T cell infiltration and activation in tissues of interest for both effector, and regulatory
subsets. Overall, very little intervention specific effect was observed within immune populations
across tissue types. However, T regulatory lymphocyte FOXP3 was also assessed and found be
significantly altered in the lungs of tumor-bearing mice, suggesting BBR paired with physical
activity may have significant immunological implications on Treg subset presence in various
tissues. Observations of MDSC infiltration into the spleen, lung, and tumor, as well as circulating
MDSC’s and production within the bone marrow showed minimal intervention specific effects.
There were non-significant increases in MDSC’s within the lungs of tumor bearing mice treated
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with BBR. It is interesting to note that both Tumor bearing animals treated with BBR had
minimal increase of Tregs and MDSC’s in the lungs. Tregs and MDSC’s are known to
participate in crosstalk, which contributes to suppression of anti-tumor immunity. Whether this
suggests a BBR specific effect within the lungs of tumor bearing animals will require more
research.
Our findings suggest that BBR may help decrease infiltration of Tregs into the tumor
microenvironment. Furthermore, the findings of this study suggest a possible relationship
between BBR and sustaining consistent long term exercise volume. The general lack of effect
seen within BBR and BBR+EX intervention groups suggests that BBR may have a very minimal
immunological influence when taken by a healthy subject.
These findings will directly inform those who practice complementary medicine and
nutraceutical supplementation, an area lacking in immunological analysis, including raising
concerns for the impact on aberrant, potentially undesirable Treg function.

66

REFERENCES

Andrzejewski, S., Gravel, S.-P., Pollak, M., & St-Pierre, J. (2014). Metformin directly acts on
mitochondria to alter cellular bioenergetics. Cancer & Metabolism, 2, 12.
https://doi.org/10.1186/2049-3002-2-12
Ashouri, J. F., & Weiss, A. (2017). Endogenous Nur77 Is a Specific Indicator of Antigen
Receptor Signaling in Human T and B Cells. The Journal of Immunology, 198(2), 657–668.
https://doi.org/10.4049/jimmunol.1601301
Berlin, G., & Enerbäck, L. (1983). Fluorescent Berberine Binding as a Marker of Secretory
Activity in Mast Cells. International Archives of Allergy and Immunology, 71(4), 332–339.
https://doi.org/10.1159/000233416
Bridges, H. R., Jones, A. J. Y., Pollak, M. N., & Hirst, J. (2014). Effects of metformin and other
biguanides on oxidative phosphorylation in mitochondria. The Biochemical Journal, 462(3),
475–487. https://doi.org/10.1042/BJ20140620
Campbell, J. M., Bellman, S. M., Stephenson, M. D., & Lisy., K. (2017). Metformin reduces allcause mortality and diseases of ageing independent of its effect on diabetes control: A
systematic review and meta-analysis. Ageing Research Reviews, 40, 31–44.
https://doi.org/10.1016/j.arr.2017.08.003
Chow, L. S., Gerszten, R. E., Taylor, J. M., Pedersen, B. K., van Praag, H., Trappe, S., Febbraio,
M. A., Galis, Z. S., Gao, Y., Haus, J. M., Lanza, I. R., Lavie, C. J., Lee, C.-H., Lucia, A.,
Moro, C., Pandey, A., Robbins, J. M., Stanford, K. I., Thackray, A. E., … Snyder, M. P.

67
(2022). Exerkines in health, resilience and disease. Nature Reviews Endocrinology, 18(5),
273–289. https://doi.org/10.1038/s41574-022-00641-2
Chuckran, C. A., Cillo, A. R., Moskovitz, J., Overacre-Delgoffe, A., Somasundaram, A. S.,
Shan, F., Magnon, G. C., Kunning, S. R., Abecassis, I., Zureikat, A. H., Luketich, J.,
Pennathur, A., Sembrat, J., Rojas, M., Merrick, D. T., Taylor, S. E., Orr, B., Modugno, F.,
Buckanovich, R., … Vignali, D. A. A. (2021). Prevalence of intratumoral regulatory T cells
expressing neuropilin-1 is associated with poorer outcomes in patients with cancer. Science
Translational Medicine, 13(623). https://doi.org/10.1126/scitranslmed.abf8495
Drake, J. C., Wilson, R. J., Laker, R. C., Guan, Y., Spaulding, H. R., Nichenko, A. S., Shen, W.,
Shang, H., Dorn, M. v., Huang, K., Zhang, M., Bandara, A. B., Brisendine, M. H.,
Kashatus, J. A., Sharma, P. R., Young, A., Gautam, J., Cao, R., Wallrabe, H., … Yan, Z.
(2021). Mitochondria-localized AMPK responds to local energetics and contributes to
exercise and energetic stress-induced mitophagy. Proceedings of the National Academy of
Sciences, 118(37). https://doi.org/10.1073/pnas.2025932118
el Khalki, L., Maire, V., Dubois, T., & Zyad, A. (2020). Berberine Impairs the Survival of Triple
Negative Breast Cancer Cells: Cellular and Molecular Analyses. Molecules, 25(3), 506.
https://doi.org/10.3390/molecules25030506
Faubert, B., Boily, G., Izreig, S., Griss, T., Samborska, B., Dong, Z., Dupuy, F., Chambers, C.,
Fuerth, B. J., Viollet, B., Mamer, O. A., Avizonis, D., DeBerardinis, R. J., Siegel, P. M., &
Jones, R. G. (2013). AMPK Is a Negative Regulator of the Warburg Effect and Suppresses
Tumor Growth In Vivo. Cell Metabolism, 17(1), 113–124.
https://doi.org/10.1016/j.cmet.2012.12.001

68
Feng, R., Shou, J.-W., Zhao, Z.-X., He, C.-Y., Ma, C., Huang, M., Fu, J., Tan, X.-S., Li, X.-Y.,
Wen, B.-Y., Chen, X., Yang, X.-Y., Ren, G., Lin, Y., Chen, Y., You, X.-F., Wang, Y., &
Jiang, J.-D. (2015). Transforming berberine into its intestine-absorbable form by the gut
microbiota. Scientific Reports, 5(1), 12155. https://doi.org/10.1038/srep12155
Freidenreich, D. J., & Volek, J. S. (2012). Immune responses to resistance exercise. Exercise
Immunology Review, 18, 8–41.
Garritson, J., Krynski, L., Haverbeck, L., Haughian, J. M., Pullen, N. A., & Hayward, R. (2020).
Physical activity delays accumulation of immunosuppressive myeloid-derived suppressor
cells. PLOS ONE, 15(6), e0234548. https://doi.org/10.1371/journal.pone.0234548
Gillespie, Z. E., Pickering, J., & Eskiw, C. H. (2016). Better Living through Chemistry: Caloric
Restriction (CR) and CR Mimetics Alter Genome Function to Promote Increased Health
and Lifespan. Frontiers in Genetics, 7. https://doi.org/10.3389/fgene.2016.00142
Griss, T., Vincent, E. E., Egnatchik, R., Chen, J., Ma, E. H., Faubert, B., Viollet, B.,
DeBerardinis, R. J., & Jones, R. G. (2015). Metformin Antagonizes Cancer Cell
Proliferation by Suppressing Mitochondrial-Dependent Biosynthesis. PLoS Biology, 13(12),
e1002309. https://doi.org/10.1371/journal.pbio.1002309
Gustafson, M. P., DiCostanzo, A. C., Wheatley, C. M., Kim, C.-H., Bornschlegl, S., Gastineau,
D. A., Johnson, B. D., & Dietz, A. B. (2017). A systems biology approach to investigating
the influence of exercise and fitness on the composition of leukocytes in peripheral blood.
Journal for ImmunoTherapy of Cancer, 5(1), 30. https://doi.org/10.1186/s40425-017-02318

69
Hagar, A., Wang, Z., Koyama, S., Serrano, J. A., Melo, L., Vargas, S., Carpenter, R., & Foley, J.
(2019). Endurance training slows breast tumor growth in mice by suppressing Treg cells
recruitment to tumors. BMC Cancer, 19(1), 536. https://doi.org/10.1186/s12885-019-5745-7
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of Cancer: The Next Generation. Cell,
144(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013
Höchst, B., Mikulec, J., Baccega, T., Metzger, C., Welz, M., Peusquens, J., Tacke, F., Knolle, P.,
Kurts, C., Diehl, L., & Ludwig-Portugall, I. (2015). Differential Induction of Ly6G and
Ly6C Positive Myeloid Derived Suppressor Cells in Chronic Kidney and Liver
Inflammation and Fibrosis. PLOS ONE, 10(3), e0119662.
https://doi.org/10.1371/journal.pone.0119662
Huang, C.-T., Workman, C. J., Flies, D., Pan, X., Marson, A. L., Zhou, G., Hipkiss, E. L., Ravi,
S., Kowalski, J., Levitsky, H. I., Powell, J. D., Pardoll, D. M., Drake, C. G., & Vignali, D.
A. A. (2004). Role of LAG-3 in Regulatory T Cells. Immunity, 21(4), 503–513.
https://doi.org/10.1016/j.immuni.2004.08.010
Iizuka, N., Miyamoto, K., Okita, K., Tangoku, A., Hayashi, H., Yosino, S., Abe, T., Morioka, T.,
Hazama, S., & Oka, M. (2000). Inhibitory effect of Coptidis Rhizoma and berberine on the
proliferation of human esophageal cancer cell lines. Cancer Letters, 148(1), 19–25.
https://doi.org/10.1016/S0304-3835(99)00264-5
Khodabakhshi, A., Akbari, M. E., Mirzaei, H. R., Seyfried, T. N., Kalamian, M., & Davoodi, S.
H. (2021). Effects of Ketogenic metabolic therapy on patients with breast cancer: A
randomized controlled clinical trial. Clinical Nutrition, 40(3), 751–758.
https://doi.org/10.1016/j.clnu.2020.06.028

70
Kim, J. B., Yu, J.-H., Ko, E., Lee, K.-W., Song, A. K., Park, S. Y., Shin, I., Han, W., & Noh, D.
Y. (2010). The alkaloid Berberine inhibits the growth of Anoikis-resistant MCF-7 and
MDA-MB-231 breast cancer cell lines by inducing cell cycle arrest. Phytomedicine, 17(6),
436–440. https://doi.org/10.1016/j.phymed.2009.08.012
Knapowski, J., Wieczorowska-Tobis, K., & Witowski, J. (2002). Pathophysiology of ageing.
Journal of Physiology and Pharmacology : An Official Journal of the Polish Physiological
Society, 53(2), 135–146.
Kwon, H., Schafer, J. M., Song, N.-J., Kaneko, S., Li, A., Xiao, T., Ma, A., Allen, C., Das, K.,
Zhou, L., Riesenberg, B., Chang, Y., Weltge, P., Velegraki, M., Oh, D. Y., Fong, L., Ma,
Q., Sundi, D., Chung, D., … Li, Z. (2022). Androgen conspires with the CD8 + T cell
exhaustion program and contributes to sex bias in cancer. Science Immunology, 7(73).
https://doi.org/10.1126/sciimmunol.abq2630
Liberti, M. v., & Locasale, J. W. (2016). The Warburg Effect: How Does it Benefit Cancer
Cells? Trends in Biochemical Sciences, 41(3), 211–218.
https://doi.org/10.1016/j.tibs.2015.12.001
Lith, S. C., Os, B. W., Seijkens, T. T. P., & Vries, C. J. M. (2020). ‘Nur’turing tumor T cell
tolerance and exhaustion: novel function for Nuclear Receptor Nur77 in immunity.
European Journal of Immunology, 50(11), 1643–1652.
https://doi.org/10.1002/eji.202048869
Liu, L., Zhang, S. X., Aeran, R., Liao, W., Lu, M., Polovin, G., Pone, E. J., & Zhao, W. (2015).
Exogenous marker-engineered mesenchymal stem cells detect cancer and metastases in a
simple blood assay. Stem Cell Research & Therapy, 6(1), 181.
https://doi.org/10.1186/s13287-015-0151-9

71
Ma, E. H., Poffenberger, M. C., Wong, A. H.-T., & Jones, R. G. (2017). The role of AMPK in T
cell metabolism and function. Current Opinion in Immunology, 46, 45–52.
https://doi.org/10.1016/j.coi.2017.04.004
Ma, W., Zhang, Y., Yu, M., Wang, B., Xu, S., Zhang, J., Li, X., & Ye, X. (2020). Corrigendum
to ‘In-vitro and in-vivo anti-breast cancer activity of synergistic effect of berberine and
exercise through promoting the apoptosis and immunomodulatory effects’ [Int.
Immunopharmacol. 87 (2020) 106787]. International Immunopharmacology, 88, 106899.
https://doi.org/10.1016/j.intimp.2020.106899
Malhotra, B., Kulkarni, G. T., Dhiman, N., Joshi, D. D., Chander, S., Kharkwal, A., Sharma, A.
K., & Kharkwal, H. (2021). Recent advances on Berberis aristata emphasizing berberine
alkaloid including phytochemistry, pharmacology and drug delivery system. Journal of
Herbal Medicine, 27, 100433. https://doi.org/10.1016/j.hermed.2021.100433
Manzanares, G., Brito-da-Silva, G., & Gandra, P. G. (2019). Voluntary wheel running: patterns
and physiological effects in mice. Brazilian Journal of Medical and Biological Research,
52(1). https://doi.org/10.1590/1414-431x20187830
McTiernan, A. (2008). Mechanisms linking physical activity with cancer. Nature Reviews
Cancer, 8(3), 205–211. https://doi.org/10.1038/nrc2325
McTiernan, A., Kooperberg, C., White, E., Wilcox, S., Coates, R., Adams-Campbell, L. L.,
Woods, N., & Ockene, J. (2003). Recreational Physical Activity and the Risk of Breast
Cancer in Postmenopausal Women. JAMA, 290(10), 1331.
https://doi.org/10.1001/jama.290.10.1331

72
Morris, L., Klanke, C., Lang, S., Lim, F.-Y., & Crombleholme, T. (2010). TdTomato and EGFP
identification in histological sections: insight and alternatives. Biotechnic & Histochemistry,
85(6), 379–387. https://doi.org/10.3109/10520290903504753
Ostrand-Rosenberg, S., & Fenselau, C. (2018). Myeloid-Derived Suppressor Cells: ImmuneSuppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their
Environment. The Journal of Immunology, 200(2), 422–431.
https://doi.org/10.4049/jimmunol.1701019
Pan, Y., Zhang, F., Zhao, Y., Shao, D., Zheng, X., Chen, Y., He, K., Li, J., & Chen, L. (2017).
Berberine Enhances Chemosensitivity and Induces Apoptosis Through Dose-orchestrated
AMPK Signaling in Breast Cancer. Journal of Cancer, 8(9), 1679–1689.
https://doi.org/10.7150/jca.19106
Patel, M. R., Chang, Y.-F., Chen, I. Y., Bachmann, M. H., Yan, X., Contag, C. H., & Gambhir,
S. S. (2010). Longitudinal, noninvasive imaging of T-cell effector function and proliferation
in living subjects. Cancer Research, 70(24), 10141–10149. https://doi.org/10.1158/00085472.CAN-10-1843
Pearce, E. L., Walsh, M. C., Cejas, P. J., Harms, G. M., Shen, H., Wang, L.-S., Jones, R. G., &
Choi, Y. (2009). Enhancing CD8 T-cell memory by modulating fatty acid metabolism.
Nature, 460(7251), 103–107. https://doi.org/10.1038/nature08097
Pereira, C. v., Machado, N. G., & Oliveira, P. J. (2008). Mechanisms of Berberine (Natural
Yellow 18)–Induced Mitochondrial Dysfunction: Interaction with the Adenine Nucleotide
Translocator. Toxicological Sciences, 105(2), 408–417.
https://doi.org/10.1093/toxsci/kfn131

73
Podhorecka, M., Ibanez, B., & Dmoszyńska, A. (2017). Metformin - its potential anti-cancer and
anti-aging effects. Postepy Higieny i Medycyny Doswiadczalnej (Online), 71(0), 170–175.
https://doi.org/10.5604/01.3001.0010.3801
Pulaski, B. A., & Ostrand-Rosenberg, S. (1998). Reduction of established spontaneous mammary
carcinoma metastases following immunotherapy with major histocompatibility complex
class II and B7.1 cell-based tumor vaccines. Cancer Research, 58(7), 1486–1493.
Ramos, J. S., Dalleck, L. C., Keith, C. E., Fennell, M., Lee, Z., Drummond, C., Keating, S. E.,
Fassett, R. G., & Coombes, J. S. (2020). Optimizing the Interaction of Exercise Volume and
Metformin to Induce a Clinically Significant Reduction in Metabolic Syndrome Severity: A
Randomised Trial. International Journal of Environmental Research and Public Health,
17(10). https://doi.org/10.3390/ijerph17103695
Ravishankaran, P., & Karunanithi, R. (2011). Clinical significance of preoperative serum
interleukin-6 and C-reactive protein level in breast cancer patients. World Journal of
Surgical Oncology, 9(1), 18. https://doi.org/10.1186/1477-7819-9-18
Rondanelli, M., Infantino, V., Riva, A., Petrangolini, G., Faliva, M. A., Peroni, G., Naso, M.,
Nichetti, M., Spadaccini, D., Gasparri, C., & Perna, S. (2020). Polycystic ovary syndrome
management: a review of the possible amazing role of berberine. Archives of Gynecology
and Obstetrics, 301(1), 53–60. https://doi.org/10.1007/s00404-020-05450-4
Simon, S. (2020, January 8). Facts & Figures 2020 Reports Largest One-year Drop in Cancer
Mortality. American Cancer Society.
Siret, C., Collignon, A., Silvy, F., Robert, S., Cheyrol, T., André, P., Rigot, V., Iovanna, J., van
de Pavert, S., Lombardo, D., Mas, E., & Martirosyan, A. (2020). Deciphering the Crosstalk

74
Between Myeloid-Derived Suppressor Cells and Regulatory T Cells in Pancreatic Ductal
Adenocarcinoma. Frontiers in Immunology, 10. https://doi.org/10.3389/fimmu.2019.03070
Takahashi, K., Nagai, N., Ogura, K., Tsuneyama, K., Saiki, I., Irimura, T., & Hayakawa, Y.
(2015). Mammary tissue microenvironment determines T cell‐dependent breast cancer‐
associated inflammation. Cancer Science, 106(7), 867–874.
https://doi.org/10.1111/cas.12685
Tang, F., Wang, D., Duan, C., Huang, D., Wu, Y., Chen, Y., Wang, W., Xie, C., Meng, J., Wang,
L., Wu, B., Liu, S., Tian, D., Zhu, F., He, Z., Deng, F., & Cao, Y. (2009). Berberine Inhibits
Metastasis of Nasopharyngeal Carcinoma 5-8F Cells by Targeting Rho Kinase-mediated
Ezrin Phosphorylation at Threonine 567. Journal of Biological Chemistry, 284(40), 27456–
27466. https://doi.org/10.1074/jbc.M109.033795
Turbitt, W. J., Xu, Y., Sosnoski, D. M., Collins, S. D., Meng, H., Mastro, A. M., & Rogers, C. J.
(2019). Physical Activity Plus Energy Restriction Prevents 4T1.2 Mammary Tumor
Progression, MDSC Accumulation, and an Immunosuppressive Tumor Microenvironment.
Cancer Prevention Research, 12(8), 493–506. https://doi.org/10.1158/1940-6207.CAPR17-0233
Turner, M. J., Kleeberger, S. R., & Lightfoot, J. T. (2005). Influence of genetic background on
daily running-wheel activity differs with aging. Physiological Genomics, 22(1), 76–85.
https://doi.org/10.1152/physiolgenomics.00243.2004
Ugel, S., de Sanctis, F., Mandruzzato, S., & Bronte, V. (2015). Tumor-induced myeloid
deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages.
Journal of Clinical Investigation, 125(9), 3365–3376. https://doi.org/10.1172/JCI80006

75
Veglia, F., Perego, M., & Gabrilovich, D. (2018). Myeloid-derived suppressor cells coming of
age. Nature Immunology, 19(2), 108–119. https://doi.org/10.1038/s41590-017-0022-x
Vita, A. A., Aljobaily, H., Lyons, D. O., & Pullen, N. A. (2021). Berberine Delays Onset of
Collagen-Induced Arthritis through T Cell Suppression. International Journal of Molecular
Sciences, 22(7), 3522. https://doi.org/10.3390/ijms22073522
Weinhold, M., Shimabukuro-Vornhagen, A., Franke, A., Theurich, S., Wahl, P., Hallek, M.,
Schmidt, A., Schinköthe, T., Mester, J., von Bergwelt-Baildon, M., & Bloch, W. (2016).
Physical exercise modulates the homeostasis of human regulatory T cells. Journal of
Allergy and Clinical Immunology, 137(5), 1607-1610.e8.
https://doi.org/10.1016/j.jaci.2015.10.035
Wong, A. K. F., Symon, R., AlZadjali, M. A., Ang, D. S. C., Ogston, S., Choy, A., Petrie, J. R.,
Struthers, A. D., & Lang, C. C. (2012). The effect of metformin on insulin resistance and
exercise parameters in patients with heart failure. European Journal of Heart Failure,
14(11), 1303–1310. https://doi.org/10.1093/eurjhf/hfs106
Wyss, L., Stadinski, B. D., King, C. G., Schallenberg, S., McCarthy, N. I., Lee, J. Y.,
Kretschmer, K., Terracciano, L. M., Anderson, G., Surh, C. D., Huseby, E. S., & Palmer, E.
(2016). Affinity for self antigen selects Treg cells with distinct functional properties. Nature
Immunology, 17(9), 1093–1101. https://doi.org/10.1038/ni.3522
Xu, X., Hu, Q., Zhou, L., Xu, L., Zou, X., Lu, F., & Yi, P. (2020). Berberine Inhibits
Gluconeogenesis in Skeletal Muscles and Adipose Tissues in Streptozotocin-induced
Diabetic Rats via LKB1-AMPK-TORC2 Signaling Pathway. Current Medical Science,
40(3), 530–538. https://doi.org/10.1007/s11596-020-2210-4

76
Yang, X., Chen, D., Long, H., & Zhu, B. (2020). The mechanisms of pathological
extramedullary hematopoiesis in diseases. Cellular and Molecular Life Sciences, 77(14),
2723–2738. https://doi.org/10.1007/s00018-020-03450-w
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008). Subsets of Myeloid-Derived
Suppressor Cells in Tumor-Bearing Mice. The Journal of Immunology, 181(8), 5791–5802.
https://doi.org/10.4049/jimmunol.181.8.5791
Zhang, H., Wei, J., Xue, R., Wu, J.-D., Zhao, W., Wang, Z.-Z., Wang, S.-K., Zhou, Z.-X., Song,
D.-Q., Wang, Y.-M., Pan, H.-N., Kong, W.-J., & Jiang, J.-D. (2010). Berberine lowers
blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor
expression. Metabolism, 59(2), 285–292. https://doi.org/10.1016/j.metabol.2009.07.029
Zhang, L. (2021). Method for voluntary oral administration of drugs in mice. STAR Protocols,
2(1), 100330. https://doi.org/10.1016/j.xpro.2021.100330
Zhang, L., Wu, X., Yang, R., Chen, F., Liao, Y., Zhu, Z., Wu, Z., Sun, X., & Wang, L. (2021).
Effects of Berberine on the Gastrointestinal Microbiota. Frontiers in Cellular and Infection
Microbiology, 10. https://doi.org/10.3389/fcimb.2020.588517
Zhao, H., Xing, C., Zhang, J., & He, B. (2021). Comparative efficacy of oral insulin sensitizers
metformin, thiazolidinediones, inositol, and berberine in improving endocrine and
metabolic profiles in women with PCOS: a network meta-analysis. Reproductive Health,
18(1), 171. https://doi.org/10.1186/s12978-021-01207-7

77

APPENDIX A
INSTITUTIONAL ANIMAL CARE AND USE
COMMITTEE APPROVAL

78

79

APPENDIX B
SUPPLEMENTAL FIGURES

80
Figure 20
Mean spleen and tumor mass represented in grams ± SD across treatment group.
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Note. Spleen mass, represented as fold change over respective non tumor control ± SEM. Tumor
mass, represented in fold change from 4T1 no treatment control in both tumor and non-tumorbearing animals. ± SEM *p<0.05, **p<0.01.

